Capri­cor gets up to $735M for Duchenne drug's US rights; PCI Biotech ends bile duct can­cer clin­i­cal tri­al

Capri­cor Ther­a­peu­tics is still chug­ging along.

The San Diego biotech signed a new col­lab­o­ra­tion with Japan­ese phar­ma com­pa­ny Nip­pon Shinyaku, whose US sub­sidiary is NS …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER